An L Moens

Summary

Affiliation: University Hospital Antwerp
Country: Belgium

Publications

  1. ncbi Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process
    A L Moens
    Department of Cardiology, University of Antwerp, Belgium
    Int J Cardiol 100:179-90. 2005
  2. ncbi Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease
    An L Moens
    Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Physiol Heart Circ Physiol 294:H1971-7. 2008
  3. ncbi Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool?
    An L Moens
    Department of Cardiology, University of Antwerp, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Antwerp, Belgium
    Chest 127:2254-63. 2005
  4. ncbi High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury
    An L Moens
    Johns Hopkins Medical Institutions, Division of Cardiology, Baltimore, MD 21205, USA
    Circulation 117:1810-9. 2008
  5. ncbi Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure
    An L Moens
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Mol Cell Cardiol 51:564-9. 2011
  6. ncbi Effect of folic acid on endothelial function following acute myocardial infarction
    An L Moens
    Department of Cardiology, University Hospital of Antwerp, Antwerp, Belgium
    Am J Cardiol 99:476-81. 2007
  7. ncbi Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease
    An L Moens
    Department of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Cardiovasc Pharmacol 50:238-46. 2007
  8. ncbi Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor
    An L Moens
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Mol Cell Cardiol 47:576-85. 2009
  9. ncbi Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system
    An L Moens
    Johns Hopkins University School of Medicine, Division of Cardiology, Baltimore, MD 21205, USA
    J Mol Cell Cardiol 48:1088-95. 2010
  10. ncbi Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy
    An L Moens
    Johns Hopkins Medical Institutions, Division of Cardiology, Baltimore, MD 21205, USA
    Circulation 117:2626-36. 2008

Collaborators

Detail Information

Publications14

  1. ncbi Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process
    A L Moens
    Department of Cardiology, University of Antwerp, Belgium
    Int J Cardiol 100:179-90. 2005
    ..g. tetrahydrobiopterin). One of such agents could be folic acid. In this review article the authors give an overview of the recent insights concerning pathogenesis and therapeutic possibilities to prevent IR-induced injury...
  2. ncbi Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease
    An L Moens
    Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Physiol Heart Circ Physiol 294:H1971-7. 2008
    ....
  3. ncbi Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool?
    An L Moens
    Department of Cardiology, University of Antwerp, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Antwerp, Belgium
    Chest 127:2254-63. 2005
    ..In this review article, the pathophysiology of FMD, based on reactive hyperemia, is extensively discussed. Furthermore, an overview is given of the actual clinical indications of FMD measurement...
  4. ncbi High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury
    An L Moens
    Johns Hopkins Medical Institutions, Division of Cardiology, Baltimore, MD 21205, USA
    Circulation 117:1810-9. 2008
    ..Here, we tested whether FA reduces myocardial ischemic dysfunction and postreperfusion injury...
  5. ncbi Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure
    An L Moens
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Mol Cell Cardiol 51:564-9. 2011
    ..This article is part of a special issue entitled ''Key Signaling Molecules in Hypertrophy and Heart Failure.''..
  6. ncbi Effect of folic acid on endothelial function following acute myocardial infarction
    An L Moens
    Department of Cardiology, University Hospital of Antwerp, Antwerp, Belgium
    Am J Cardiol 99:476-81. 2007
    ..Folic acid can be recommended to improve postinfarction endothelial dysfunction in patients with normo- and hyperhomocysteinemia...
  7. ncbi Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease
    An L Moens
    Department of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Cardiovasc Pharmacol 50:238-46. 2007
    ..This review summarizes these recent studies focusing on the biochemistry and pharmacology of BH4 and its potential role for treating cardiovascular disease...
  8. ncbi Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor
    An L Moens
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Mol Cell Cardiol 47:576-85. 2009
    ..These data suggest a cardioprotective role for the beta3-AR in modulating oxidative stress and adverse remodeling in the failing heart...
  9. ncbi Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system
    An L Moens
    Johns Hopkins University School of Medicine, Division of Cardiology, Baltimore, MD 21205, USA
    J Mol Cell Cardiol 48:1088-95. 2010
    ....
  10. ncbi Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy
    An L Moens
    Johns Hopkins Medical Institutions, Division of Cardiology, Baltimore, MD 21205, USA
    Circulation 117:2626-36. 2008
    ..Oxidative stress linked to nitric oxide synthase (NOS) uncoupling may play an important role. We tested whether tetrahydrobiopterin (BH4) can recouple NOS and reverse preestablished advanced hypertrophy, fibrosis, and dysfunction...
  11. ncbi Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders
    Jan F Gielis
    Department of Vascular and Thoracic Surgery, University of Antwerp, Antwerp, Belgium
    Free Radic Biol Med 50:765-76. 2011
    ....
  12. ncbi Thrombospondin-4 is required for stretch-mediated contractility augmentation in cardiac muscle
    Oscar H Cingolani
    Division of Cardiology, Department of Medicine, Department of Biomedical Engineering, The Johns Hopkins University Medical Institutions, Baltimore, MD 21205, USA
    Circ Res 109:1410-4. 2011
    ..Because levels of the matricellular protein thrombospondin-4 (TSP4) rapidly rise in hypertension and are elevated in cardiac stress overload and heart failure, we hypothesized that TSP4 is involved in this adaptive mechanism...
  13. ncbi Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5
    Eiki Takimoto
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Circulation 115:2159-67. 2007
    ..The potential role of differential cGMP and protein kinase G stimulation by these 2 modulators was also studied...
  14. ncbi Tetrahydrobiopterin and cardiovascular disease
    An L Moens
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Arterioscler Thromb Vasc Biol 26:2439-44. 2006
    ..This review discusses the biochemistry, physiology, and evolving therapeutic potential of BH4 for cardiovascular disease...